RPh NOW vs. Biosimilar Utilizzo e statistiche

RPh Now uses peer-to-peer technology to connect pharmacists and pharmacy technicians with businesses that request them on an as needed basis. Just like other peer-to-peer apps the pharmacy requests the services of other users that will cover their staffing needs. Just create your account, choose the areas you are willing to work at and wait for the notifications to come in. It doesn’t matter if you are fully employed and want to make some extra money on your day off or just looking to work a few hours a week, RPh Now is free for pharmacists and pharmacy technicians with no hidden charges or fees. You just have to accept a shift and show up!
  • App Store di Apple
  • Gratis
  • Settore Medico

Classifica degli store

- -

Biologic drugs offer important treatment options for patients suffering from auto-immune disorders such as rheumatoid arthritis and for common cancers including breast and colon. Biosimilar and interchangeable products, which can loosely be thought of as ‘generic’ biologics, are important for promoting competition and driving down costs. The FDA maintains a list of approved biosimilars in the Purple Book. The Biosimilar iOS app provides a handy reference to the Purple Book as well as important information related to prescribing and dispensing for clinicians and pharmacists navigating this complex area of drug therapeutics. ** Disclaimer ** - non-medical users should ask for a doctor’s advice in addition to using this app and before making any medical decisions.
  • App Store di Apple
  • A pagamento
  • Settore Medico

Classifica degli store

- -

RPh NOWRanking a confronto con Biosimilar

Confronta la tendenza di classifica RPh NOW nei ultimi 28 giorni rispetto a Biosimilar

BiosimilarBiosimilar- -

Rank

Classifica RPh NOW vs. Biosimilar per paese a confronto

Confronta la tendenza di classifica RPh NOW nei ultimi 28 giorni rispetto a Biosimilar

Nessun dato da visualizzare

Fai confronti con qualsiasi sito con la nostra prova gratuita

Inizia
RPh NOW VS.
Biosimilar

gennaio 1, 2025